<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Clear Cell Renal Cell Carcinoma - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Clear Cell Renal Cell Carcinoma</span>
        </nav>

        <header class="page-header">
            <h1>Clear Cell Renal Cell Carcinoma</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0005005" target="_blank">
                        MONDO:0005005
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">renal cell carcinoma</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, characterized by biallelic inactivation of the VHL tumor suppressor gene in over 90% of cases. VHL loss stabilizes hypoxia-inducible factors (HIF-1Œ± and HIF-2Œ±), driving expression of angiogenic and growth-promoting genes including VEGF, PDGF, and TGF-Œ±. This molecular understanding led to development of VEGF/VEGFR inhibitors and the more recent HIF-2Œ± inhibitor belzutifan, representing a paradigm shift toward targeting the root cause of the disease.
            </p>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Histopathology</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">solid tumor</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Carcinoma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">VHL-associated ccRCC</div>
                
                <div class="item-desc">Hereditary form occurring in Von Hippel-Lindau disease patients with germline VHL mutations. Tumors are typically bilateral and multifocal. Patients also develop hemangioblastomas, pheochromocytomas, and pancreatic neuroendocrine tumors.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Sporadic ccRCC</div>
                
                <div class="item-desc">Comprises 95% of ccRCC cases. Somatic VHL inactivation occurs through mutation, deletion, or promoter hypermethylation. Additional mutations in chromatin remodeling genes (PBRM1, BAP1, SETD2) affect prognosis.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">VHL Tumor Suppressor Inactivation</div>
                
                <div class="item-desc">Biallelic VHL loss is the initiating event in ccRCC. The VHL protein normally targets HIF-Œ± subunits for ubiquitin-mediated degradation under normoxic conditions. Without functional VHL, HIF-Œ± accumulates and constitutively activates hypoxia response genes.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        kidney epithelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002518" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cellular response to hypoxia
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0071456" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        proteasome-mediated ubiquitin-dependent protein catabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0043161" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37085424" target="_blank">PMID:37085424</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"These include somatic gene mutations such as VHL, PBRM1, SETD2, and BAP1"</div>
                
                
                <div class="evidence-explanation">This comprehensive review confirms VHL as the primary genomic biomarker and driver mutation in ccRCC.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">HIF-2Œ± Stabilization</div>
                
                <div class="item-desc">Without VHL-mediated degradation, HIF-2Œ± protein accumulates in the cytoplasm and translocates to the nucleus where it dimerizes with HIF-1Œ≤ (ARNT) to form an active transcription factor. HIF-2Œ± is the critical HIF isoform in ccRCC.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        protein stabilization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0050821" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">VEGF-Driven Angiogenesis</div>
                
                <div class="item-desc">HIF-2Œ± transcriptionally activates VEGF (vascular endothelial growth factor), driving tumor neovascularization. The resulting hypervascular phenotype is characteristic of ccRCC and the basis for VEGFR-targeted therapy.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        angiogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001525" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        vascular endothelial growth factor receptor signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0048010" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Growth Factor Pathway Activation</div>
                
                <div class="item-desc">HIF-2Œ± activates transcription of growth-promoting genes including TGF-Œ± (which activates EGFR signaling) and cyclin D1 (which promotes cell cycle progression). This drives tumor cell proliferation independent of angiogenesis.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Epigenetic Dysregulation</div>
                
                <div class="item-desc">Secondary mutations in chromatin remodeling genes (PBRM1 in 40%, BAP1 in 15%, SETD2 in 15%) contribute to ccRCC progression. BAP1 mutations are associated with higher grade tumors and worse prognosis compared to PBRM1 mutations. These mutations cooperate with VHL loss to drive tumor evolution.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        chromatin remodeling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006338" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚ö† ABNORMAL
    </span>
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37085424" target="_blank">PMID:37085424</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"These include somatic gene mutations such as VHL, PBRM1, SETD2, and BAP1"</div>
                
                
                <div class="evidence-explanation">This review confirms PBRM1, SETD2, and BAP1 as recurrent genomic biomarkers in ccRCC contributing to epigenetic dysregulation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ffedd5; color: #c2410c;">‚ú∂</div>
                <h2 class="card-title">Histopathology</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box histopathology-box">
                <div class="item-name">
                    Clear Cell Renal Cell Carcinoma
                    
                    <span class="histopathology-freq">VERY_FREQUENT</span>
                    
                </div>
                
                <div class="item-desc">Clear cell RCC is the most common histologic subtype of renal cell carcinoma.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39196544" target="_blank">PMID:39196544</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Clear cell RCC is the most common histologic subtype"</div>
                
                
                <div class="evidence-explanation">Abstract reports clear cell RCC as the most common histologic subtype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    VEGF_Driven_Angiogenesis[&#34;VEGF-Driven Angiogenesis&#34;]
    HIF_2Œ±_Stabilization[&#34;HIF-2Œ± Stabilization&#34;]
    Growth_Factor_Pathway_Activation[&#34;Growth Factor Pathway Activation&#34;]
    VHL_Tumor_Suppressor_Inactivation[&#34;VHL Tumor Suppressor Inactivation&#34;]
    Epigenetic_Dysregulation[&#34;Epigenetic Dysregulation&#34;]

    VHL_Tumor_Suppressor_Inactivation --&gt; HIF_2Œ±_Stabilization
    HIF_2Œ±_Stabilization --&gt; VEGF_Driven_Angiogenesis
    HIF_2Œ±_Stabilization --&gt; Growth_Factor_Pathway_Activation
    Epigenetic_Dysregulation --&gt; Growth_Factor_Pathway_Activation

    style VEGF_Driven_Angiogenesis fill:#dbeafe
    style HIF_2Œ±_Stabilization fill:#dbeafe
    style Growth_Factor_Pathway_Activation fill:#dbeafe
    style VHL_Tumor_Suppressor_Inactivation fill:#dbeafe
    style Epigenetic_Dysregulation fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Renal Mass
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Genitourinary</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0009726" target="_blank">
                            HP:0009726
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hematuria
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Genitourinary</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000790" target="_blank">
                            HP:0000790
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fatigue
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Constitutional</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                            HP:0012378
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Weight Loss
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Constitutional</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001824" target="_blank">
                            HP:0001824
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Metastatic Disease
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002664" target="_blank">
                            HP:0002664
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    VHL
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Germline and Somatic Inactivating Mutations)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PBRM1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Inactivating Mutations)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BAP1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Inactivating Mutations)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Nephrectomy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Surgical resection (partial or radical nephrectomy) is the primary treatment for localized ccRCC. Cytoreductive nephrectomy may benefit selected patients with metastatic disease.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    VEGFR Tyrosine Kinase Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other kinases to block HIF-driven angiogenesis. First-line options for metastatic ccRCC, often combined with immunotherapy.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Belzutifan
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">First-in-class HIF-2Œ± inhibitor that directly targets the driver of ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing promise in sporadic ccRCC. Represents mechanism-based targeted therapy.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Immune Checkpoint Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001002" target="_blank">
                            MAXO:0001002
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Nivolumab, pembrolizumab, and ipilimumab provide durable responses in ccRCC. Often combined with VEGFR TKIs as first-line therapy for intermediate/poor risk metastatic disease.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    HIF-2Œ± Pathway Activation
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Clear Cell Renal Cell Carcinoma
description: &gt;-
  Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney
  cancer, characterized by biallelic inactivation of the VHL tumor suppressor
  gene in over 90% of cases. VHL loss stabilizes hypoxia-inducible factors (HIF-1Œ±
  and HIF-2Œ±), driving expression of angiogenic and growth-promoting genes including
  VEGF, PDGF, and TGF-Œ±. This molecular understanding led to development of VEGF/VEGFR
  inhibitors and the more recent HIF-2Œ± inhibitor belzutifan, representing a
  paradigm shift toward targeting the root cause of the disease.
categories:
- Genitourinary Cancer
- Hereditary Cancer Syndrome
parents:
- renal cell carcinoma
has_subtypes:
- name: VHL-associated ccRCC
  description: &gt;-
    Hereditary form occurring in Von Hippel-Lindau disease patients with germline
    VHL mutations. Tumors are typically bilateral and multifocal. Patients also
    develop hemangioblastomas, pheochromocytomas, and pancreatic neuroendocrine tumors.
- name: Sporadic ccRCC
  description: &gt;-
    Comprises 95% of ccRCC cases. Somatic VHL inactivation occurs through mutation,
    deletion, or promoter hypermethylation. Additional mutations in chromatin
    remodeling genes (PBRM1, BAP1, SETD2) affect prognosis.
pathophysiology:
- name: VHL Tumor Suppressor Inactivation
  description: &gt;-
    Biallelic VHL loss is the initiating event in ccRCC. The VHL protein normally
    targets HIF-Œ± subunits for ubiquitin-mediated degradation under normoxic
    conditions. Without functional VHL, HIF-Œ± accumulates and constitutively
    activates hypoxia response genes.
  cell_types:
  - preferred_term: kidney epithelial cell
    term:
      id: CL:0002518
      label: kidney epithelial cell
  biological_processes:
  - preferred_term: cellular response to hypoxia
    modifier: INCREASED
    term:
      id: GO:0071456
      label: cellular response to hypoxia
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    modifier: DECREASED
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  downstream:
  - target: HIF-2Œ± Stabilization
    description: Loss of VHL-mediated degradation allows HIF-2Œ± protein accumulation
  evidence:
  - reference: PMID:37085424
    supports: SUPPORT
    snippet: &#34;These include somatic gene mutations such as VHL, PBRM1, SETD2, and BAP1&#34;
    explanation: This comprehensive review confirms VHL as the primary genomic biomarker and driver mutation in ccRCC.
- name: HIF-2Œ± Stabilization
  description: &gt;-
    Without VHL-mediated degradation, HIF-2Œ± protein accumulates in the cytoplasm
    and translocates to the nucleus where it dimerizes with HIF-1Œ≤ (ARNT) to form
    an active transcription factor. HIF-2Œ± is the critical HIF isoform in ccRCC.
  biological_processes:
  - preferred_term: protein stabilization
    modifier: INCREASED
    term:
      id: GO:0050821
      label: protein stabilization
  downstream:
  - target: VEGF-Driven Angiogenesis
    description: HIF-2Œ± transcriptionally activates VEGF expression
  - target: Growth Factor Pathway Activation
    description: HIF-2Œ± induces TGF-Œ± and cyclin D1 expression
- name: VEGF-Driven Angiogenesis
  description: &gt;-
    HIF-2Œ± transcriptionally activates VEGF (vascular endothelial growth factor),
    driving tumor neovascularization. The resulting hypervascular phenotype is
    characteristic of ccRCC and the basis for VEGFR-targeted therapy.
  biological_processes:
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
  - preferred_term: vascular endothelial growth factor receptor signaling pathway
    modifier: INCREASED
    term:
      id: GO:0048010
      label: vascular endothelial growth factor receptor signaling pathway
- name: Growth Factor Pathway Activation
  description: &gt;-
    HIF-2Œ± activates transcription of growth-promoting genes including TGF-Œ±
    (which activates EGFR signaling) and cyclin D1 (which promotes cell cycle
    progression). This drives tumor cell proliferation independent of angiogenesis.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
- name: Epigenetic Dysregulation
  description: &gt;-
    Secondary mutations in chromatin remodeling genes (PBRM1 in 40%, BAP1 in 15%,
    SETD2 in 15%) contribute to ccRCC progression. BAP1 mutations are associated
    with higher grade tumors and worse prognosis compared to PBRM1 mutations.
    These mutations cooperate with VHL loss to drive tumor evolution.
  biological_processes:
  - preferred_term: chromatin remodeling
    modifier: ABNORMAL
    term:
      id: GO:0006338
      label: chromatin remodeling
  downstream:
  - target: Growth Factor Pathway Activation
    description: Epigenetic changes enhance proliferative gene expression programs
  evidence:
  - reference: PMID:37085424
    supports: SUPPORT
    snippet: &#34;These include somatic gene mutations such as VHL, PBRM1, SETD2, and BAP1&#34;
    explanation: This review confirms PBRM1, SETD2, and BAP1 as recurrent genomic biomarkers in ccRCC contributing to 
      epigenetic dysregulation.
histopathology:
- name: Clear Cell Renal Cell Carcinoma
  finding_term:
    preferred_term: Clear Cell Renal Cell Carcinoma
    term:
      id: NCIT:C4033
      label: Clear Cell Renal Cell Carcinoma
  frequency: VERY_FREQUENT
  description: Clear cell RCC is the most common histologic subtype of renal cell carcinoma.
  evidence:
  - reference: PMID:39196544
    supports: SUPPORT
    snippet: &#34;Clear cell RCC is the most common histologic subtype&#34;
    explanation: Abstract reports clear cell RCC as the most common histologic subtype.

phenotypes:
- category: Genitourinary
  name: Renal Mass
  frequency: VERY_FREQUENT
  diagnostic: true
  description: &gt;-
    ccRCC typically presents as a solid renal mass, often discovered incidentally
    on imaging. Classic triad of flank pain, hematuria, and palpable mass occurs
    in minority of cases.
  phenotype_term:
    preferred_term: Renal neoplasm
    term:
      id: HP:0009726
      label: Renal neoplasm
- category: Genitourinary
  name: Hematuria
  frequency: FREQUENT
  description: &gt;-
    Gross or microscopic hematuria occurs when tumor invades the collecting system.
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
- category: Constitutional
  name: Fatigue
  frequency: FREQUENT
  description: &gt;-
    Fatigue is common and may be related to paraneoplastic syndromes or
    advanced disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Constitutional
  name: Weight Loss
  frequency: OCCASIONAL
  description: &gt;-
    Unintentional weight loss may occur with metastatic disease.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Systemic
  name: Metastatic Disease
  frequency: FREQUENT
  description: &gt;-
    ccRCC commonly metastasizes to lung, bone, liver, and brain. Metastases
    are often highly vascular and may be hypervascular on imaging.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
biochemical:
- name: HIF-2Œ± Pathway Activation
  notes: &gt;-
    VHL loss leads to constitutive HIF-2Œ± stabilization and activation of
    downstream targets including VEGF, PDGF, TGF-Œ±, and cyclin D1.
genetic:
- name: VHL
  association: Germline and Somatic Inactivating Mutations
  inheritance:
  - name: Autosomal Dominant
  notes: &gt;-
    VHL (3p25.3) is inactivated in over 90% of ccRCC through mutation, deletion,
    or promoter methylation. Germline VHL mutations cause Von Hippel-Lindau
    disease with increased ccRCC risk. Somatic VHL loss is the initiating
    event in sporadic ccRCC.
- name: PBRM1
  association: Somatic Inactivating Mutations
  notes: &gt;-
    PBRM1 (chromatin remodeling SWI/SNF complex) mutations occur in 40% of
    ccRCC. Associated with better prognosis compared to BAP1 mutations.
- name: BAP1
  association: Somatic Inactivating Mutations
  notes: &gt;-
    BAP1 (deubiquitinase) mutations occur in 15% of ccRCC. Associated with
    higher grade tumors and worse prognosis. Mutually exclusive with PBRM1.
treatments:
- name: Nephrectomy
  description: &gt;-
    Surgical resection (partial or radical nephrectomy) is the primary
    treatment for localized ccRCC. Cytoreductive nephrectomy may benefit
    selected patients with metastatic disease.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: VEGFR Tyrosine Kinase Inhibitors
  description: &gt;-
    Sunitinib, pazopanib, axitinib, and cabozantinib target VEGFR and other
    kinases to block HIF-driven angiogenesis. First-line options for
    metastatic ccRCC, often combined with immunotherapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: sunitinib
      term:
        id: CHEBI:38940
        label: sunitinib
    - preferred_term: pazopanib
      term:
        id: CHEBI:71219
        label: pazopanib
    - preferred_term: axitinib
      term:
        id: CHEBI:66910
        label: axitinib
    - preferred_term: cabozantinib
      term:
        id: CHEBI:72317
        label: cabozantinib
- name: Belzutifan
  description: &gt;-
    First-in-class HIF-2Œ± inhibitor that directly targets the driver of
    ccRCC pathogenesis. Approved for VHL-associated ccRCC and showing
    promise in sporadic ccRCC. Represents mechanism-based targeted therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Immune Checkpoint Inhibitors
  description: &gt;-
    Nivolumab, pembrolizumab, and ipilimumab provide durable responses
    in ccRCC. Often combined with VEGFR TKIs as first-line therapy for
    intermediate/poor risk metastatic disease.
  treatment_term:
    preferred_term: immunotherapy procedure
    term:
      id: MAXO:0001002
      label: immunotherapy procedure
disease_term:
  preferred_term: clear cell renal cell carcinoma
  term:
    id: MONDO:0005005
    label: clear cell renal carcinoma

classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Clear_Cell_Renal_Cell_Carcinoma.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>